(R)-1-((10-BROMO-3,6,7-TRIMETHOXYPHENANTHREN-9-YL)METHYL)-N,N-DIETHYLPIPERIDINE-2-CARBOXAMIDE

/static/temp/default.svg

Search structure


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	CIRONTZJNGLJOR-XMMPIXPASA-N
Smiles	CCN(CC)C(=O)[C@H]1CCCCN1Cc2c(Br)c3ccc(OC)cc3c4cc(OC)c(OC)cc24
InChI	InChI=1S/C28H35BrN2O4/c1-6-30(7-2)28(32)24-10-8-9-13-31(24)17-23-22-16-26(35-5)25(34-4)15-21(22)20-14-18(33-3)11-12-19(20)27(23)29/h11-12,14-16,24H,6-10,13,17H2,1-5H3/t24-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C28H35BrN2O4
Molecular Weight	543.49
AlogP	5.44
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	8.0
Polar Surface Area	51.24
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	35.0

Assay Description	Organism	Bioactivity	Reference
Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus infection protective effect at 500 ug/mL measured 3 to 4 days post inoculation	Tobacco mosaic virus	37.2 %
Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus infection curative effect at 500 ug/mL measured 3 to 4 days post inoculation	Tobacco mosaic virus	31.5 %
Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus inactivation effect at 500 ug/mL measured 3 to 4 days post inoculation	Tobacco mosaic virus	28.6 %
Antiviral activity against Tobacco mosaic virus (TMV) assessed as inhibition of viral growth at 500 ug/mL	Tobacco mosaic virus	39.2 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2229818
PubChem	76325997

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).